- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07725835
Effect of FPP on Cutaneous Barrier Integrity (FPP OSATO)
Pilot Study of Fermented Papaya Preparation (FPP) Impact on Transepidermal Water Loss of Skin on Face, Arms, and Hands
This pilot study will test how Fermented Papaya Preparation (FPP) impacts overall TEWL of areas that commonly display diminished barrier function, such as the skin from face, arms, and hands. Areas of diminished barrier function are defined as those not visible to the eye but identified as areas of high transepidermal water loss (TEWL) as measured by a non-invasive pen-like device. A TEWL value of 20 or higher at a location would be considered high TEWL. Participants will attend 5 visits over 20 weeks, with 12-weeks of FPP treatment, and 8-weeks of follow-up.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Savita Khanna, PhD
- Phone Number: 412-624-5500
- Email: savitakhanna@pitt.edu
Study Contact Backup
- Name: Scot King, DPT
- Email: scot.king@pitt.edu
Study Locations
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15219
- McGowan Institute for Regenerative Medicine
-
Contact:
- Savita Khanna, PhD
- Phone Number: 412-624-5500
- Email: savitakhanna@pitt.edu
-
Contact:
- Scot King, DPT
- Email: scot.king@pitt.edu
-
Principal Investigator:
- Savita Khanna, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 50-75 years
- Willing to allow collection of 3 blood samples (Baseline, Week 12 and Week 20)
- Willing to log daily compliance with FPP intake during the study period (12 weeks)
- Absence of active systemic disease per investigator judgement.
- No current use of immunosuppressant or immunomodulatory medications.
- No active dermatological conditions at measurement sites that could impair measure, per investigator judgement.
- Investigator determination of general good health.
Exclusion Criteria:
- Co-morbidity or concurrent medication that the Investigator deems impactful to patient safety or ability to adhere to FPP dosage.
- Co-morbidity or concurrent medication that the Investigator deems confounding to outcome measure (i.e., topical or systemic steroid).
- Current or history of allergy to FPP ingredients: Dextrose, Carica papaya, or Food yeast.
- Concurrent participation in another interventional trial that may impact measures, per investigator judgement.
- Uncontrolled diabetes (A1c >7%).
- Open wounds or actively receiving Wound Care services.
- Pregnant or breastfeeding women.
- Current use of warfarin.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Fermented Papaya Preparation
Fermented Papaya Preparation Supplement |
Immun'Age Fermented Papaya Preparation |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Transepidermal Water Loss (TEWL)
Time Frame: From enrollment to the end of FPP at 12 weeks.
|
9 anatomical sites. Unit g/m²/h |
From enrollment to the end of FPP at 12 weeks.
|
|
Skin surface pH
Time Frame: From enrollment to the end of FPP at 12 weeks.
|
9 anatomical sites. |
From enrollment to the end of FPP at 12 weeks.
|
|
Skin surface temperature
Time Frame: From enrollment to the end of FPP at 12 weeks.
|
9 anatomical sites. Unit Celsius |
From enrollment to the end of FPP at 12 weeks.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Monocyte Inflammation Marker
Time Frame: From enrollment to the end of FPP at 12 weeks.
|
CD16 |
From enrollment to the end of FPP at 12 weeks.
|
|
Glucose Levels
Time Frame: From enrollment to the end of FPP at 12 weeks.
|
Unit mg/dL |
From enrollment to the end of FPP at 12 weeks.
|
|
HbA1c Levels
Time Frame: From enrollment to the end of FPP at 12 weeks.
|
Percentage |
From enrollment to the end of FPP at 12 weeks.
|
|
Complete Blood Count (CBC)
Time Frame: From enrollment to the end of FPP at 12 weeks.
|
Absolute Counts |
From enrollment to the end of FPP at 12 weeks.
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Savita Khanna, PhD, University of Pittsburgh
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- STUDY26010104
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.